Track Indoco Remedies Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: -4.91 %
Low
244.8
High
262.3
1 Month returns: 7.01 %
Low
229.1
High
265.1
1 Year returns: -27.00 %
Low
162.2
High
341.1
3 Year CAGR: -9.33 %
Low
162.2
High
415.0
5 Year CAGR: -10.98 %
Low
162.2
High
530.3
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Indoco Remedies Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Indoco Remedies Ltd. Shareholding Pattern
Quarterly breakdown of Indoco Remedies Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Indoco Remedies Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Indoco Remedies Ltd.?
The current share price of Indoco Remedies Ltd. is ₹ 247.45 as of 17 Jul 2026.
What is the market capitalisation of Indoco Remedies Ltd.?
The market capitalisation of Indoco Remedies Ltd. stands at ₹ 2,282.06 Cr.
What is the PE ratio of Indoco Remedies Ltd.?
The Price-to-Earnings (PE) ratio of Indoco Remedies Ltd. is - as of the latest trailing twelve months data.
What is the ROE and ROCE of Indoco Remedies Ltd.?
Indoco Remedies Ltd. has a Return on Equity (ROE) of -9.70% and a Return on Capital Employed (ROCE) of 0.76% as per the latest financial reports.
What is the 52-week high and low of Indoco Remedies Ltd.?
The 52-week high of Indoco Remedies Ltd. is - and the 52-week low is -.
What is the dividend yield of Indoco Remedies Ltd.?
The dividend yield of Indoco Remedies Ltd. is 0.08% based on the current market price.
What is the FII and DII holding in Indoco Remedies Ltd.?
Foreign Institutional Investors (FII) hold 0.94%, Domestic Institutional Investors (DII) hold 17.54% and retail/public investors hold 19.47% of Indoco Remedies Ltd. shares.
What sector does Indoco Remedies Ltd. belong to?
Indoco Remedies Ltd. operates in the Healthcare sector. 0% of analysts have a Buy or Strong Buy rating on Indoco Remedies Ltd. with a consensus target price of ₹ 272.00, implying 9.92% upside from current levels.
What is the beta of Indoco Remedies Ltd.?
The beta of Indoco Remedies Ltd. is 0.85, indicating its price volatility relative to the broader market. Over the past 1 year, Indoco Remedies Ltd. has delivered an absolute return of -24.44%.
What is the RSI of Indoco Remedies Ltd.?
The 14-day Relative Strength Index (RSI) of Indoco Remedies Ltd. is 55.82, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.
Stock Analysis
Fundamental analysis overview of Indoco Remedies Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Consistently pays dividend
The company has not missed dividend payments once in the last 10 financial years
What is Dividend streak?
Negative
Stock is fairly expensive with negative EPS on a trailing 12-month basis
Earnings yield of -4.17% indicates that the stock is very expensive and has a negative EPS on a trailing 12-month basis
What is Earnings yield (E/P)?
Analysts have been downgrading forward EPS estimates
Analyst EPS estimate (consensus) for forward EPS has decreased by -16.51% in the last 3 months, indicating weak earnings momentum
What is Earnings upgrade (3M)?
Low and declining ROE
The company reported low ROE of -9.7% for 12-month ended 31 Mar 2026 and ROE declined by -277 bps from 1 year ago
What is ROE (FY)?
Low EPS growth and lower than median growth of industry
The company delivered moderate EPS growth of -33.78% for 12-month ended 31 Mar 2026 and the growth was 41.9 percentage points lower than median growth of industry
What is EPS growth (1Y)?
Low dividend yield
The company has a low dividend yield of 0.08%
What is Dividend yield?
Neutral
Low operating margin but improving trend
The company reported low operating margin of 0.83% for 12-month ended 31 Mar 2026 but operating margin improved by 171 bps from 1 year ago
What is Operating profit margin?
Moderate revenue growth and in line with median growth of industry
The company delivered moderate revenue growth of 10.84% for 12-month ended 31 Mar 2026 and the growth was 0.39 percentage points lower than median growth of industry
What is Sales growth (1Y)?
Median: 11.23
Value 10.84
-82.35114662
Reasonable Debt to Equity, and has been stable
The company has reasonable Debt to Equity of 1.16 as on 31 Mar 2026 and Debt to Equity increased marginally by 0.19 in the last 1 year
What is Debt to Equity?
Company's earnings are of moderate quality
Earnings quality score of 55.3 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion
What is Earnings quality score?
55.3 / 100
No red flags found!
No significant red flags found in the stock.
Company Profile
Overview of Indoco Remedies Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Indoco Remedies Limited is an India-based fully integrated, research-oriented pharmaceutical company. The Company is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The Company caters to both Domestic and International markets. Its products include SENSODENT-K, HOMIDE, DEXOREN-S, LORCHEK-MR, SENSOFORM, KIDODENT, NINAF, KARVOL PLUS, CYCLOPAM, LIGNOX+ADRENLINE, NOXA, CITAL-UTI, RENOLEN, REXIDIN-M, CITAL, SENSODENT-KF, CARMICIDE, TOBAREN-DM, FEBREX PLUS, SCABEX, CLOBEN-G, MOFLOREN-BF, OTOREX, ZINCOREN, SENOLIN, LIGNOX, HEMSYL, FEDRIS, REXIDIN, VEPAN, OXIPOD, TURBOCORT, MACUCHEK, and DENTOGEL. The Company has around 11 manufacturing facilities, seven for finished dosage forms (FDFs) and four for active pharmaceutical ingredients (APIs), supported by a research and development center and a clinical research organization facility.
Indoco Remedies Limited is an India-based fully integrated, research-oriented pharmaceutical company. The Company is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The Company caters to both Domestic and International ...
Key personnel
Mr. Pramod Ghorpade
Chief Financial Officer
Mr. Ramanathan Hariharan
Compliance Officer, Company Secretary, Head - Legal
Mr. Suresh Govind KareD
Non-Executive Non-Independent Chairman of the Board
Ms. Aditi Kare PanandikarD
Chief Executive Officer, Managing Director, Executive Director